Huperzine A for Alzheimer's disease: a systematic review and meta-analysis of randomized clinical trials.

<h4>Background</h4>Huperzine A is a Chinese herb extract used for Alzheimer's disease. We conducted this review to evaluate the beneficial and harmful effect of Huperzine A for treatment of Alzheimer's disease.<h4>Methods</h4>We searched for randomized clinical tria...

Descripción completa

Guardado en:

Detalles Bibliográficos
Autores principales:	Guoyan Yang, Yuyi Wang, Jinzhou Tian, Jian-Ping Liu
Formato:	article
Lenguaje:	EN
Publicado:	Public Library of Science (PLoS) 2013
Materias:	Medicine R Science Q
Acceso en línea:	https://doaj.org/article/01426edd48dc4a959458e46f8ddbc23c
Etiquetas:	Agregar Etiqueta Sin Etiquetas, Sea el primero en etiquetar este registro!

id	oai:doaj.org-article:01426edd48dc4a959458e46f8ddbc23c
record_format	dspace
spelling	oai:doaj.org-article:01426edd48dc4a959458e46f8ddbc23c2021-11-18T08:54:06ZHuperzine A for Alzheimer's disease: a systematic review and meta-analysis of randomized clinical trials.1932-620310.1371/journal.pone.0074916https://doaj.org/article/01426edd48dc4a959458e46f8ddbc23c2013-01-01T00:00:00Zhttps://www.ncbi.nlm.nih.gov/pmc/articles/pmid/24086396/pdf/?tool=EBIhttps://doaj.org/toc/1932-6203<h4>Background</h4>Huperzine A is a Chinese herb extract used for Alzheimer's disease. We conducted this review to evaluate the beneficial and harmful effect of Huperzine A for treatment of Alzheimer's disease.<h4>Methods</h4>We searched for randomized clinical trials (RCTs) of Huperzine A for Alzheimer's disease in PubMed, Cochrane Library, and four major Chinese electronic databases from their inception to June 2013. We performed meta-analyses using RevMan 5.1 software. (Protocol ID: CRD42012003249).<h4>Results</h4>20 RCTs including 1823 participants were included. The methodological quality of most included trials had a high risk of bias. Compared with placebo, Huperzine A showed a significant beneficial effect on the improvement of cognitive function as measured by Mini-Mental State Examination (MMSE) at 8 weeks, 12 weeks and 16 weeks, and by Hastgawa Dementia Scale (HDS) and Wechsler Memory Scale (WMS) at 8 weeks and 12 weeks. Activities of daily living favored Huperzine A as measured by Activities of Daily Living Scale (ADL) at 6 weeks, 12 weeks and 16 weeks. One trial found Huperzine A improved global clinical assessment as measured by Clinical Dementia Rating Scale (CDR). One trial demonstrated no significant change in cognitive function as measured by Alzheimer's disease Assessment Scale-Cognitive Subscale (ADAS-Cog) and activity of daily living as measured by Alzheimer's disease Cooperative Study Activities of Daily Living Inventory (ADCS-ADL) in Huperzine A group. Trials comparing Huperzine A with no treatment, psychotherapy and conventional medicine demonstrated similar findings. No trial evaluated quality of life. No trial reported severe adverse events of Huperzine A.<h4>Conclusions</h4>Huperzine A appears to have beneficial effects on improvement of cognitive function, daily living activity, and global clinical assessment in participants with Alzheimer's disease. However, the findings should be interpreted with caution due to the poor methodological quality of the included trials.Guoyan YangYuyi WangJinzhou TianJian-Ping LiuPublic Library of Science (PLoS)articleMedicineRScienceQENPLoS ONE, Vol 8, Iss 9, p e74916 (2013)
institution	DOAJ
collection	DOAJ
language	EN
topic	Medicine R Science Q
spellingShingle	Medicine R Science Q Guoyan Yang Yuyi Wang Jinzhou Tian Jian-Ping Liu Huperzine A for Alzheimer's disease: a systematic review and meta-analysis of randomized clinical trials.
description	<h4>Background</h4>Huperzine A is a Chinese herb extract used for Alzheimer's disease. We conducted this review to evaluate the beneficial and harmful effect of Huperzine A for treatment of Alzheimer's disease.<h4>Methods</h4>We searched for randomized clinical trials (RCTs) of Huperzine A for Alzheimer's disease in PubMed, Cochrane Library, and four major Chinese electronic databases from their inception to June 2013. We performed meta-analyses using RevMan 5.1 software. (Protocol ID: CRD42012003249).<h4>Results</h4>20 RCTs including 1823 participants were included. The methodological quality of most included trials had a high risk of bias. Compared with placebo, Huperzine A showed a significant beneficial effect on the improvement of cognitive function as measured by Mini-Mental State Examination (MMSE) at 8 weeks, 12 weeks and 16 weeks, and by Hastgawa Dementia Scale (HDS) and Wechsler Memory Scale (WMS) at 8 weeks and 12 weeks. Activities of daily living favored Huperzine A as measured by Activities of Daily Living Scale (ADL) at 6 weeks, 12 weeks and 16 weeks. One trial found Huperzine A improved global clinical assessment as measured by Clinical Dementia Rating Scale (CDR). One trial demonstrated no significant change in cognitive function as measured by Alzheimer's disease Assessment Scale-Cognitive Subscale (ADAS-Cog) and activity of daily living as measured by Alzheimer's disease Cooperative Study Activities of Daily Living Inventory (ADCS-ADL) in Huperzine A group. Trials comparing Huperzine A with no treatment, psychotherapy and conventional medicine demonstrated similar findings. No trial evaluated quality of life. No trial reported severe adverse events of Huperzine A.<h4>Conclusions</h4>Huperzine A appears to have beneficial effects on improvement of cognitive function, daily living activity, and global clinical assessment in participants with Alzheimer's disease. However, the findings should be interpreted with caution due to the poor methodological quality of the included trials.
format	article
author	Guoyan Yang Yuyi Wang Jinzhou Tian Jian-Ping Liu
author_facet	Guoyan Yang Yuyi Wang Jinzhou Tian Jian-Ping Liu
author_sort	Guoyan Yang
title	Huperzine A for Alzheimer's disease: a systematic review and meta-analysis of randomized clinical trials.
title_short	Huperzine A for Alzheimer's disease: a systematic review and meta-analysis of randomized clinical trials.
title_full	Huperzine A for Alzheimer's disease: a systematic review and meta-analysis of randomized clinical trials.
title_fullStr	Huperzine A for Alzheimer's disease: a systematic review and meta-analysis of randomized clinical trials.
title_full_unstemmed	Huperzine A for Alzheimer's disease: a systematic review and meta-analysis of randomized clinical trials.
title_sort	huperzine a for alzheimer's disease: a systematic review and meta-analysis of randomized clinical trials.
publisher	Public Library of Science (PLoS)
publishDate	2013
url	https://doaj.org/article/01426edd48dc4a959458e46f8ddbc23c
work_keys_str_mv	AT guoyanyang huperzineaforalzheimersdiseaseasystematicreviewandmetaanalysisofrandomizedclinicaltrials AT yuyiwang huperzineaforalzheimersdiseaseasystematicreviewandmetaanalysisofrandomizedclinicaltrials AT jinzhoutian huperzineaforalzheimersdiseaseasystematicreviewandmetaanalysisofrandomizedclinicaltrials AT jianpingliu huperzineaforalzheimersdiseaseasystematicreviewandmetaanalysisofrandomizedclinicaltrials
_version_	1718421182566367232

Huperzine A for Alzheimer's disease: a systematic review and meta-analysis of randomized clinical trials.

Ejemplares similares